Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells
and either kill them or deliver tumor-killing substances to them without harming normal
cells.
PURPOSE: This phase II trial is studying combination chemotherapy plus trastuzumab to see how
well it works in treating patients with advanced, recurrent, or metastatic colorectal cancer.